Every Form 4 that Sensus Healthcare Inc (SRTS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SRTS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SRTS filings page.
Sensus Healthcare, Inc. (SRTS) director Eric Sachetta reported open-market purchases of the company’s Common Stock. On 2026-08-31, he purchased 27,304 shares at $3.538 per share, and on 2026-08-28, he purchased 37,537 shares at $3.437 per share, for a total of 64,841 shares acquired. The filing also lists an indirect holding of 2,093 shares held through his spouse as of 2026-08-28.
Sensus Healthcare, Inc. (SRTS) director Eric Sachetta reported open-market purchases of the company’s common stock. On August 27, 2026, he purchased 10,925 shares at $3.181 per share, and on August 26, 2026 he purchased 9,708 shares at $3.289 per share, for a total of 20,633 shares acquired directly. The filing also reports an indirect holding of 2,093 shares held through his spouse.
Sensus Healthcare, Inc. (SRTS) director Eric Sachetta reported an open-market purchase of the company’s Common Stock. On 2026-08-24, he purchased 34,697 shares at a price of $3.254 per share, bringing his directly held position to 209,310 shares. He also reports 2,093 shares held indirectly through his spouse.
Sensus Healthcare, Inc. (SRTS) reported that its Chief Executive Officer and director, Joseph C. Sardano, purchased 20,000 shares of common stock on 2026-08-20 in an open-market or private transaction at $3.0243 per share. Following this transaction, he directly owns 1,220,293 shares of SRTS common stock.
Sensus Healthcare, Inc. (SRTS) director Eric Sachetta reported open-market purchases of 31,000 shares of common stock. He bought 24,000 shares on August 20, 2026 at $3.1280 per share and 7,000 shares on August 21, 2026 at $3.2540 per share, all held directly. A separate entry shows 2,093 shares held indirectly through his spouse. The filing indicates these transactions were not made pursuant to a Rule 10b5-1 trading plan.
Sensus Healthcare director Eric Sachetta reported an open-market purchase of company stock. On May 12, 2026, he bought 1,500 shares of Sensus Healthcare, Inc. common stock at $3.335 per share.
Following this transaction, he directly holds 143,613 common shares and also reports indirect ownership of 2,093 shares held by his spouse.
Sensus Healthcare director Eric Sachetta filed an amended Form 4 to correct previously reported holdings. The filing clarifies that his spouse holds 2,093 shares of Sensus Healthcare common stock indirectly attributed to him. Earlier Forms 4 had inadvertently omitted these indirectly owned shares, and this amendment updates the reported ownership without reflecting any new buy or sell transaction.
Sensus Healthcare, Inc. chief financial officer Javier Rampolla reported a routine share adjustment linked to equity compensation. On July 21, 2022, 3,935 shares of common stock were withheld at $10.51 per share to cover his tax obligation from vested restricted stock. After this withholding, he beneficially owned 48,114 shares of common stock directly. The amended filing also corrects an earlier Form 4 that had overstated his holdings by 742 shares, revising the previously reported 48,856 shares to the accurate 48,114 shares as of that date.
Sensus Healthcare, Inc. reported that Chief Operating Officer Magdalena Martinez had 741 shares of common stock withheld at $2.66 per share to satisfy withholding taxes arising from the vesting of restricted stock on December 19, 2023. After this tax-withholding disposition, she held 12,013 shares of common stock, including 7,500 shares of restricted stock, as of that date. The amended filing corrects a prior Form 4 that had understated her holdings as 9,759 shares.
Sensus Healthcare, Inc. director Eric Sachetta reported buying additional company shares in the open market. On this Form 4, he acquired 2,000 shares of common stock at an average price of $3.81 per share. After this transaction, his directly owned holdings increased to 142,113 common shares.
Sensus Healthcare reported an insider stock grant to one of its leaders. Director and officer Michael Sardano, who serves as President and General Counsel, acquired 40,000 shares of common stock on 12/12/2025 through a restricted stock award under the Sensus Healthcare, Inc. 2017 Equity Incentive Plan.
The restricted shares will vest in four equal annual installments starting on the first anniversary of the grant date. Following this grant, Sardano directly beneficially owns 158,839 shares of Sensus Healthcare common stock, with an additional 1,000 shares held by his spouse, for which he disclaims beneficial ownership.
Sensus Healthcare, Inc. director and officer Michael Sardano filed an amended insider ownership report. The amendment clarifies that his spouse holds 1,000 shares of Sensus Healthcare common stock, which are reported as indirectly owned through his spouse.
The report states that Sardano disclaims beneficial ownership of these 1,000 shares, even though they are attributable to him for reporting purposes. This amendment corrects an earlier report that had shown no indirect ownership of the company’s common stock.
Sensus Healthcare, Inc. director reports open-market stock purchase. A company director filed a Form 4 disclosing the purchase of 7,000 shares of Sensus Healthcare common stock on 11/21/2025 at a price of $3.93 per share. Following this transaction, the director now beneficially owns 140,113 shares, held directly. The filing was made by a single reporting person in their capacity as a director of Sensus Healthcare.
Sensus Healthcare, Inc. (SRTS) reported an insider share purchase by a director. On 11/13/2025, the reporting person bought 2,500 shares of common stock in an open market transaction coded "P" at a price of $4.50 per share. After this transaction, the director beneficially owns 133,113 shares of Sensus Healthcare common stock, held directly. This filing reflects a change in insider ownership rather than an operating or financial update for the company.
Sensus Healthcare, Inc. (SRTS) reported an insider stock purchase by its Chief Executive Officer and director, Joseph C. Sardano. On 11/18/2025, he acquired 25,000 shares of Sensus Healthcare common stock in an open-market purchase transaction coded "P" at an average price of $4.03 per share, as noted in the explanation that this figure represents the average price per share.
Following this transaction, Sardano beneficially owns 1,200,293 shares of Sensus Healthcare common stock in direct ownership. The filing is made on Form 4 as a report by one reporting person in his capacity as both director and Chief Executive Officer of the company.
Sensus Healthcare, Inc. (SRTS) director and officer Michael Sardano reported a personal purchase of company stock. On 11/18/2025, he acquired 1,000 shares of common stock at a price of $3.80 per share, coded as a purchase transaction. Following this trade, he now beneficially owns 118,839 shares of Sensus Healthcare common stock with direct ownership.
Sardano is listed as a Director and as an Officer with the title President and General Counsel, indicating both governance and executive responsibilities at the company. This filing is made on Form 4, which reports changes in ownership of the company’s equity securities by insiders.
Sensus Healthcare, Inc. insider Michael Sardano, who serves as President, General Counsel, and a director of the company, reported open-market purchases of SRTS common stock. On 11/11/2025, he bought 1,000 shares of common stock at a price of $4.26 per share, bringing his directly owned holdings to 117,839 shares.
On the same date, his spouse purchased 766 shares at $4.27 per share and 234 shares at $4.34 per share, for a total of 1,000 shares held in the spouse’s name. The filing notes that Sardano disclaims beneficial ownership of the shares held by his spouse.
Sensus Healthcare (SRTS) officer and director Michael Sardano reported open‑market purchases on November 11, 2025.
He acquired 1,000 shares of common stock at $4.26 held directly. Additional purchases were reported for his spouse of 766 shares at $4.27 and 234 shares at $4.24. Following these transactions, Sardano held 117,839 shares directly. He disclaims beneficial ownership of his spouse’s shares. Sardano serves as President and General Counsel and is also a Director.
Sensus Healthcare (SRTS) reported an insider stock purchase on Form 4. President and General Counsel, and Director, Michael Sardano bought 1,000 shares of common stock on 11/11/2025 at $4.26 per share.
Following the transaction, he beneficially owned 117,839 shares, held directly. This filing reflects routine insider activity and updates Sardano’s reported ownership position.